As result of the capital increase with pre-emptive subscription rights that ended on 23 March, the number of subscribed shares consists of 1,021,712 shares amounting to € 1,021,712. Consequently, the share capital of Neuron Bio, S.A. amounts to € 9,346,712. Funds raised will be used for the promotion and development of AlzTest®, the aid testRead more →
Figure. Member states of Patent Cooperation Treaty (PCT) are shown in blue. On 10 March 2016 Neuron Bio (NEU.MC) has extended its European patent application for the Alzheimer’s diagnostic aid test AlzTest®, to 148 contracting states of the Patent Cooperation Treaty (PCT) with file number PCT/EP2016/055090. The content of the international patent application that protectsRead more →
Granada, 7 March 2016. Neuron Bio has been designated by Merck Millipore as reference laboratory for the Milliplex® immunoassays technology focused on the identification of biomarkers. Neuron Bio uses the Merck Millipore Milliplex® technology since 2011, employed by the company in the creation of AlzTest®, its test to aid in the diagnosis of Alzheimer’s disease.Read more →
Neuron Bio has signed an agreement with Centro de Diagnóstico for marketing its non-invasive diagnostic test for Alzheimer’s disease, which is carried out through a blood test. The diagnostic test, which is based on a method protected by European patent application, is carried out by analyzing biomarkers in blood. Thus, it allows the specialist in neurologicalRead more →
The Spanish Ministry of Economy and Competitiveness has awarded the grant by the ERDF INNTERCONECTA program for the implementation of a consortium project with the multinational company AMC INNOVA JUICE AND DRINKS and the leading IERA (Instituto Extremeño de Reproducción Asistida). The aim of the project is to develop specific functional food in order toRead more →
Español
English